• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Royalty Pharma Plc Cl A (NQ: RPRX )

    28.96 +0.28 (+0.98%)
    Streaming Delayed Price Updated: 11:28 AM EDT, Jul 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 558,830
    Open 28.79
    Bid (Size) 28.96 (2)
    Ask (Size) 28.97 (3)
    Prev. Close 28.68
    Today's Range 28.74 - 29.07
    52wk Range 25.20 - 31.66
    Shares Outstanding 388,132,400
    Dividend Yield 2.76%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
    From Royalty Pharma plc
    Via GlobeNewswire

    Performance

    YTD
    +2.44%
    +2.44%
    1 Month
    +7.66%
    +7.66%
    3 Month
    +3.02%
    +3.02%
    6 Month
    -0.52%
    -0.52%
    1 Year
    -7.24%
    -7.24%

    More News

    Read More
    Royalty Pharma Declares Third Quarter 2024 Dividend
    From Royalty Pharma plc
    Via GlobeNewswire
    Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
    Via Investor's Business Daily
    NASDAQ:RPRX: good value for what you're paying.
    Via Chartmill
    Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
    Via InvestorPlace
    7 Biotech Stocks to Buy on the Dip: June 2024
    Via InvestorPlace
    Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
    Via Benzinga
    June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
    Via InvestorPlace
    Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
    From Royalty Pharma plc
    Via GlobeNewswire
    Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
    Via Benzinga
    Exposures Product Safety
    Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
    Via Investor's Business Daily
    Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
    From Royalty Pharma plc
    Via GlobeNewswire
    Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
    Via Benzinga
    Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
    From Royalty Pharma plc; Cytokinetics
    Via GlobeNewswire
    7 Dividend Stocks to Buy at a 52-Week Low
    Via InvestorPlace
    Royalty Pharma to Present at Upcoming Investor Conferences
    From Royalty Pharma plc
    Via GlobeNewswire
    RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Royalty Pharma Reports First Quarter 2024 Results
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
    From Royalty Pharma plc
    Via GlobeNewswire
    Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
    Via Benzinga
    Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Declares Second Quarter 2024 Dividend
    From Royalty Pharma plc
    Via GlobeNewswire
    3 Pharma Stocks to Sell in April Before They Crash & Burn
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.